Research In Cancer and Tumor

International Journal of Cancer and Tumor is a peer-reviewed international journal which provides a forum for prompt communication of original and innovative research findings that have relevance to understanding the etiology of cancer and to improving the treatment and survival of patients.

Georg F. Weber

Editorial Board Member of Research In Cancer and Tumor

Associate Professor, University of Cincinnati, USA

Research Areas



1988M.D.University of Wurzburg, FRG
1988Ph.DUniversity of Wurzburg, FRG
1981B.ScOhm Gymnasium, Erlangen, FRG


2006-presentFaculty Member, Graduate Program in Cell and Cancer Biology, University of Cincinnati, OH
2004-presentCancer Center, University of Cincinnati Medical Center, Cincinnati, OH
2004-presentAssociate Professor, University of Cincinnati Academic Health Center, College of Pharmacy, Cincinnati, OH
2000-2004Faculty Member, Graduate Program in Immunology, Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, MA
2000-2003Associate Member, Cancer Center, New England Medical Center/Tufts University
1999-2004Assistant Professor, Tufts University School of Medicine, Boston MA
1996Visiting Scientist, Biomedical Engineering Research Center, Boston University, Boston, MA
1993-2000Instructor, Harvard Medical School, Boston MA

Academic Achievement

1981 Award for Excellence, Ohm-Gymnasium, Erlangen, FRG
1989-1991 Deutsche Forschungsgemeinschaft (German Research Foundation) Postdoctoral Fellowship
2005-2006 First Professional Year Faculty Excellence Award, College of Pharmacy, University of Cincinnati
2010 Plenary Speaker, Oncology'10 WSEAS Conference Cambridge, UK
2010 Chairperson (and Invited Speaker), BIT's 3rd World Cancer Congress, Shanghai, China
2010 Research Excellence Award, College of Pharmacy, University of Cincinnatia

Publications: Conferences/Workshops/Symposiums/Journals/Books

[1]  Weber GF, Cantor H. Differential roles of osteopontin/Eta-1 in early and late lpr disease. Clinical and Experimental Immunology 2001;126:578-583.
[2]  Weber GF. The metastasis gene osteopontin: A candidate target for cancer therapy. Biochimica et Biophysica Acta 2001;1552:61-85.
[3]  Weber GF, Bronson R, Ilagan J, Cantor H, Schmitz R, Mak TW. Absence of CD44 prevents sarcoma metastasis. Cancer Research 2002;62:2281-2286.
[4]  Zhang G, He B, Weber GF. Growth factor signaling induces metastasis genes in transformed cells. A molecular connection between Akt kinase and osteopontin in breast cancer. Molecular and Cellular Biology 2003;23:6507-6519.
[5]  He B, Weber GF. Phosphorylation of NF-kB proteins by cyclic GMP-dependent kinase: A noncanonical pathway to NF-kB activation. The European Journal of Biochemistry 2003;270:2174-2185.
[6]  Weber GF. The absence of CD44 ameliorates Faslpr/lpr disease. Autoimmunity 2004;37:1-8.
[7]  He B, Weber GF. Synergistic activation of the CMV promoter by NF-kB P50 and Cyclic GMP-Dependent Kinase. Biochemical and Biophysical Research Communications 2004;321:13-20.
[8]  Craig-Mylius C, Weber GF, Coburn JL, Glickstein LG. Borrelia burgdorferi, an extracellular pathogen, circumvents osteopontin in inducing an inflammatory cytokine response. Journal of Leukocyte Biology 2005;77:710-718.
[9]  Mesa C Jr, Mirza M, Mitsutake N, Sartor M, Medvedovic M, Tomlinson C, Knauf JA, Weber GF, Fagin JA. Conditional activation of the RET/PTC3 and B-RAFV600E oncoproteins in thyroid cells is associated with unique patterns of gene expression that predict distinct functional properties and a preferential role of BRAF in extracellular matrix remodeling. Cancer Research 2006;66:6521-6529.
[10]  Weber GF. 2007. Molecular Mechanisms of Cancer. Dordrecht (Springer).
[11]  Whalen KA, Weber GF, Benjamin TL, Schaffhausen BS. Polyomavirus middle T antigen induces the transcription of osteopontin, a gene important for migration of transformed cells. The Journal of Virology 2008;82:4946-4954.
[12]  Syed M, Fenoglio-Preiser C, Skau KA, Weber GF. Acetylcholinesterase supports anchorage independence in colon cancer. Clinical and Experimental Metastasis 2008;25:787-798.
[13]  Weber GF. Molecular mechanisms of metastasis. Cancer Letters 2008;270:181-190.
[14]  Weber GF. Drug targets in cancer metastasis. In: American Association for Cancer Research 100th Annual Meeting Education Book. Philadelphia (AACR) 2009;137-140.
[15]  Sullivan J, Blair L, Alnajar A, Aziz T, Ng CY, Chipitsyna G, Gong Q, Witkiewicz W, Weber GF, Yeo CJ, Arafat HA. Expression of a pro-metastatic splice variant of Osteopontin, OPNc, in human pancreatic ductal adenocarcinoma. Surgery 2009;146:232-240.
[16]  Weber GF. 2010. Molecular genetics and metastasis. Encyclopedia of Life Sciences, DOI 10.1002/9780470015902.a0022447.
[17]  Weber GF. Toward a molecular classification of cancer. Toxicology 2010;278:195-198.
[18]  Weber GF, Lett GS, Haubein NC. Meta-analysis of Osteopontin as a clinical cancer marker. Oncology Reports 2011;25:433-441.
[19]  Tilli TM, Franco VF, Robbs BK, Wanderley JL, Silva F, Duarte de Mello K, Viola JPB, Weber GF, Gimba ERP. Osteopontin-c splicing isoform contributes to ovarian cancer progression. Molecular Cancer Research 2011;9:280-293.
[20]  Zhang R, Pan X, Ma S, Weber GF, Zhang G. Osteopontin enhances the expression and activity of MMP-2 via the SDF-1/CXCR4 axis in hepatocellular carcinoma cell lines. PLoS ONE, 2011, in press.
[21]  Weber GF. 2011. The cancer biomarker Osteopontin: Combination with other markers. Cancer Genomics and Proteomics. 2011, in press.